Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
Conditions
Interventions
MT-5111 (experimental study drug)
Locations
30
United States
Mayo Clinic (Arizona)
Phoenix, Arizona, United States
St. Joseph Heritage Healthcare
Fullerton, California, United States
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
Cedars-Sinai Medical Center
Santa Monica, California, United States
UCLA Hematology & Oncology
Santa Monica, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Start Date
November 12, 2019
Primary Completion Date
February 1, 2023
Completion Date
April 27, 2023
Last Updated
June 18, 2023
Lead Sponsor
Molecular Templates, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions